Mural Oncology Past Earnings Performance
Past criteria checks 0/6
Mural Oncology has been growing earnings at an average annual rate of 2.1%, while the Biotechs industry saw earnings growing at 19.3% annually.
Key information
2.1%
Earnings growth rate
22.5%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | n/a |
| Return on equity | -88.3% |
| Net Margin | n/a |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
No updates
Recent updates
Here's Why We're Watching Mural Oncology's (NASDAQ:MURA) Cash Burn Situation
Nov 26
Here's Why We're A Bit Worried About Mural Oncology's (NASDAQ:MURA) Cash Burn Situation
Jul 17We're Keeping An Eye On Mural Oncology's (NASDAQ:MURA) Cash Burn Rate
Mar 28Recent Spin Mural Oncology At An Attractive Discount To Cash And Portfolio Value
Mar 04Revenue & Expenses Breakdown
How Mural Oncology makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 0 | -154 | 46 | 113 |
| 30 Jun 24 | 0 | -173 | 46 | 126 |
| 31 Mar 24 | 0 | -192 | 44 | 140 |
| 31 Dec 23 | 0 | -207 | 41 | 154 |
| 30 Sep 23 | 0 | -196 | 30 | 155 |
| 30 Jun 23 | 0 | -196 | 29 | 160 |
| 31 Mar 23 | 0 | -191 | 28 | 157 |
| 31 Dec 22 | 0 | -190 | 28 | 157 |
Quality Earnings: MURA is currently unprofitable.
Growing Profit Margin: MURA is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if MURA's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Unable to compare MURA's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: MURA is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (16.6%).
Return on Equity
High ROE: MURA has a negative Return on Equity (-88.31%), as it is currently unprofitable.